19 June 2013
Keywords: oral, isis, yields, encouraging, ph, data, usa-based
Article | 13 February 2006
USA-based Isis Pharmaceuticals says that a Phase I study of an oral formulation of its anticholesterol drug candidate, ISIS 301012, has
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 February 2006
18 June 2013
© 2013 thepharmaletter.com